In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Effect of different generations of drug-eluting stents on the prognosis of patients with stenting unprotected left main coronary artery.

Session Poster Session 4

Speaker Associate Professor Daniil Maximkin

Congress : Heart Failure 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session
  • FP Number : P2242

Authors : Z KH Shugushev (Moscow,RU), D A Maximkin (Moscow,RU), AG Chepurnoy (Moscow,RU), OO Safonova (Moscow,RU)

Authors:
Z KH Shugushev1 , D A Maximkin1 , AG Chepurnoy1 , OO Safonova1 , 1Peoples Friendship University of Russia (RPFU) - Moscow - Russian Federation ,

Citation:

Aims : to evaluate long-term results of patients who underwent unprotected left main coronary artery (ULMCA) interventions with different generations of drug-eluting stents (DES).

Methods : there is long-term comparative clinical outcome data of percutaneous coronary intervention (PCI) in unprotected left main coronary artery (LMCA) disease treated with the single (provisional-T) stent technique in the drug-eluting stent (DES). The primary outcome was the occurrence of major adverse cardiac events (MACE) defined as total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR). Data from a single center registry, which included 189 patients, who ULMCA PCI with different generations DES. All interventions were conducted by final «kissing-balloon» dilatation with high pressure balloons and under IVUS/OCT guidence. Long-term results were assessed by following criteria: frequency of MACE (death, myocardial infarction, re-intervention), IVUS//OCT data (residual area of vessel lumen in the proximal segment of LM, zone of bifurcation, the ostia of LAD and LCx).

Results : there were 72 patients receiving everolimus-eluting stent (EES) second generation («Xience V»), 68 patients receiving biolimus-eluting stent (BES) third generation («Nobori»), and 49 patients receiving everolimus-eluting stent (EES) IVth generation («Synergy»). During 12-months follow-up, the PS adjusted Cox-proportional hazard ratio (HR) was not significantly different between the three groups for total death, cardiac death, TLR and MI. The narrowing of LCX ostial area at follow-up was more pronounced in BES compared with EES (13.2% vs. 2.5%, respectively, p<0.001). Linear regression analysis showed a high correlation between the number of stent struts in LCX ostium and ostial area narrowing (r=0.771, p<0.001). Re-intervention was required in the LCX ostial area only in 3,1% of cases in group second generation EES and in 5,6% of third generation BES. During 3-years follow-up, there was no statistical difference in major adverse cardiovascular events, cardiac death, myocardial infarction and stent thrombosis between the groups different generations stents (HR: 0.63, 95% Confidence interval (CI): 0.33-1.17; P = 0.149).

Conclusions : The endovascular treatment of patients with unprotected left main  bifurcation lesions with different generations of drug-eluting stents is associated with good long-term clinical outcomes. Clinical outcome seems to be independent of lesion complexity and the number of stent struts in LCX ostium. There are no differences in clinical events among patients receiving different generation drug-eluting stents for ULMCA disease.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are